opacin-neo trial rfs and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
Published 4 years ago • 202 plays • Length 2:52Download video MP4
Download video MP3
Similar videos
-
1:39
opacin and opacin-neo: neoadjuvant immunotherapy for advanced melanoma
-
1:16
neoadjuvant ipi nivo in stage iii melanoma: updates from opacin & opacin-neo
-
2:53
opacin-neo: tmb and ifn-γ identified as biomarkers of pathologic response in melanoma
-
0:57
circulating immune cell subsets in patients with melanoma from the opacin-neo trial
-
3:15
optimal neoadjuvant io in resectable stage iii melanoma: interferon gamma signature analysis
-
1:34
opacin and opacin-neo trial updates
-
1:54
opacin-neo and prado: personalized neoadjuvant io for melanoma based on pathologic response
-
2:43
tumor characteristics of patients with recurrence after neoadjuvant ipi nivo in melanoma
-
2:33
opacin-neo & prado 3-year results in stage iii melanoma: personalized neoadjuvant io benefits
-
3:44
neoadjuvant approaches in melanoma
-
1:20
neopele: neoadjuvant pembrolizumab and lenvatinib in resectable stage iii melanoma
-
6:16
optimal neoadjuvant combination scheme of ipi nivo for melanoma
-
2:46
neoadjuvant therapy in bulky stage iii melanoma
-
2:32
neoadjuvant biomarker analysis of neorhea: palbociclib in er /her2- bc
-
1:48
dr. blank on the opacin, opacin-neo trials in stage iii macroscopic melanoma
-
2:45
long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: abc trial data
-
1:12
investigators present updated results of the opacin trial for melanoma
-
1:55
neoadjuvant ipilimumab plus nivolumab in stage iii melanoma
-
0:46
the benefits of nivolumab and relatlimab in melanoma